Mineralys Therapeutics Reports New Data Of Analysis From Its Pivotal Phase 3 Launch-HTN Study

Mineralys Therapeutics, Inc. (Nasdaq: MLYS) announced new data from its pivotal Phase 3 Launch-HTN trial, revealing that 46% of participants treated with lorundrostat achieved the recommended office systolic blood pressure target of <130 mmHg by Week 12. These findings were presented at the American Heart Association Hypertension Scientific Sessions 2026, held from October 7-11 in Arlington, VA.